# Head-to-head Study of Tegoprazan 50 mg BID Plus Amoxicillin 1 g TID vs. Vonoprazan 20 mg BID Plus Amoxicillin 1 g TID for H. Pylori Eradication

> **NCT07242456** · PHASE2,PHASE3 · RECRUITING · sponsor: **First People's Hospital of Hangzhou** · enrollment: 240 (estimated)

## Conditions studied

- Helicobacter Pylori Infection

## Interventions

- **DRUG:** Tegoprazan
- **DRUG:** Amoxicillin
- **DRUG:** Vonoprazan

## Key facts

- **NCT ID:** NCT07242456
- **Lead sponsor:** First People's Hospital of Hangzhou
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-17
- **Primary completion:** 2025-11-15
- **Final completion:** 2026-01-31
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07242456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07242456, "Head-to-head Study of Tegoprazan 50 mg BID Plus Amoxicillin 1 g TID vs. Vonoprazan 20 mg BID Plus Amoxicillin 1 g TID for H. Pylori Eradication". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT07242456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*